Pfizer to invest $350 mln in China biotech hub, first in Asia

SHANGHAI, June 28 (Reuters) - Pfizer Inc will invest $350 million to build a biotech centre in China, the latest in a series of moves by pharma industry giants to set up shop in the world's no. 2 drugs market with the aim of securing faster approvals for their products.